Conference begins
  • No dates present
  • Industry-Supported Symposia

    Wednesday July 6

    Sanofi Genzyme

    12:00-13:30

    Room: Grand Ballroom Centre

    Luncheon Symposium supported by Sanofi Genzyme

    Pompe Medical Expert Symposium

    Chair & Moderator: Dr. Vera Bril

    • Introduction of Late Onset Pompe Disease: Dr. Mark Tarnopolsky, McMaster University, Hamilton, ON
    • Diagnostic Strategies of LGMW Including Next Generation Sequencing: Dr. Matthew Harms, Columbia University, New York, NY

    See here for more details.

    17:15-18:15

    Room: Osgoode Ballroom West

    Evening Symposium supported by Akashi Therapeutics

    Multi-pathway Approach to DMD Treatment

    Chair: Diana Escolar

    • Antifibrotics: HT-100 For The Treatment Of DMD: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.
    • Modulating Calcium Homeostasis: AT-300 Effects In MDX Model Of DMD: Ernest D. Bush, Ph.D, Chief Scientific Officer, Akashi Therapeutics, Inc.
    • A Novel Approach To Building Muscle In DMD: DT-200, Selective Androgen Receptor Modulator: Diana Escolar, MD, Chief Medical Officer, Akashi Therapeutics, Inc.

    See here for more details.

     

     

    Thursday July 7

    7:00-8:00

    Room: Grand Ballroom West

    Breakfast Symposium supported by Terumo BCT

    The immunomodulatory role of plasma exchange in PNS & Neuromuscular diseases: A Presentation & clinical debate

    • Plasma exchange immune-modulation & mechanism of action: Prof. Hans-Peter Hartung, Heinrich-Heine-Universität, Düsseldorf, Germany
    • Clinical debate on the place of plasma exchange in PNS & neuromuscular diseases (acute & chronic), addressing current evidence & unmet medical needs:
      • Prof. Jean-Marc Leger, MD, FAAN, University Hospital Pitié-Salpêtrière, Paris, France
      • Prof. Mazen Dimachkie, University of Kansas Medical Center, Kansas City, KS

    See here for more details.

    7:00-8:00

    Room: Osgoode Ballroom East

    Breakfast Symposium supported by CSL Behring

    Updates in Myasthenia Gravis

    Chair: Dr. Vera Bril

    • Novel Clinical Assessment Methods in Myasthenia Gravis: Dr. Carolina Barnett, University Health Network and University of Toronto, ON
    • Recent Updates in the Treatment of Myasthenia Gravis: Dr. Zaeem A. Siddiqi, University of Alberta Hospital, Edmonton, AB

    See here for more details and to RSVP.

    7:00-8:00

    Room: Osgoode Ballroom West

    Breakfast Symposium supported by Idera

    Advances in Myositis: Immune Mechanisms of Disease, Current Clinical Practice and Future Directions

    Moderator: Kirsten Gruis, MD, Senior Medical Director, Rare Diseases, Idera Pharmaceuticals

    • Toll-Like Receptors and Innate Immune Mechanisms of Muscle Disease: Kanneboyina Nagaraju, DVM, PhD, George Washington University School of Medicine and Health Sciences; Children’s National Medical Center, Washington, DC
    • Current Understanding of Standards of Care and Management of Inflammatory Myopathies: Anthony A. Amato, MD, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

    See here for more details and to RSVP.

    Alnylam 17:15-18:15

    Room: Osgoode Ballroom West

    Evening Symposium supported by Alnylam

    The Patient Journey: From symptom onset to new treatment horizons in hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

    • Patient journey and unmet medical needs in hATTR-PN
    • Natural history, treatment options and clinical assessment tools in hATTR-PN
    • Development of RNAi therapeutics as a potential treatment option for patients wtih hATTR-PN

    Presenters:

    • Michelle Mezei, MD (Canada)
    • P James Dyck, MD (USA)
    • Alejandra Gonzalez Duarte, MD (Mexico)

    See here for more details.

    Friday July 8

    12:00-13:30

    Room: Osgoode Ballroom West

    Luncheon Symposium supported by PTC Therapeutics

    The Evolving Management of Duchenne Muscular Dystrophy

    Chair: Jean K. Mah

    • The Evolving Understanding of Clinical End Points and Meaningfulness: Jean K. Mah, MD, MSc, FRCPC, University of Calgary; Alberta Children's Hospital, Calgary, AB
    • The Future of Duchenne Treatments: Perry Shieh, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA

    See here for more details and to RSVP.

     

     

    Saturday July 9

    7:00-8:00

    Room: Grand Ballroom West

    Breakfast Symposium supported by Alexion

    Recognizing the Patient with Refractory Myasthenia Gravis: An Interactive Workshop

    Moderator: Karen Gondek

    • Refractory MG
    • Assessment tools and MG‐ADL

    Presenters:

    • Srikanth Muppidi, MD, Stanford School of Medicine, Stanford, CA
    • Richard J. Nowak, MD, MS, Yale School of Medicine, New Haven, CT
    • Nicholas J. Silvestri, MD, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
    • Gil I. Wolfe, MD, FAAN, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY

    See here for more details.

    Grifols7:00-8:00

    Room: Osgoode Ballroom West

    Breakfast Symposium supported by Grifols

    Measuring response and need to continue treatment in CIDP: Moving from ICE trial outcome measures to future clinical biomarker

    Chair: Hans Katzberg, MD

    • Residual conduction block after IVIG as a predictor of relapse in CIDP: Norman Latov, MD, Weill Cornell Medical Center, New York, NY
    • Real-time ultrasound monitoring of same lesions as a biomarker of therapeutic efficacy in CIDP: Francis Walker, MD, Wake Forest University, Winston-Salem, NC

    See here for more details.

    12:00-13:30

    Room: Grand Ballroom West

    Luncheon Symposium supported by Santhera

    Advances in pulmonary care in DMD

    Chair: Oscar H Mayer

    • Overview of respiratory function measures: Oscar H Mayer, The Children's Hospital of Philadelphia, PA
    • The natural history of respiratory functional decline in DMD: Erik Henricson, Physical Medicine and Rehabilitation Neuromuscular Research Center, Sacramento, CA
    • Current standards of care and future perspectives: Oscar H Mayer
    • Treatment strategies to slow decline in respiratory function in DMD - Report of the DELOS Phase III trial: Gunnar Buyse, University of Leuven, Belgium

    See here for more details.

    Follow ICNMD 2016:

    Twitter

    CONFERENCE NEWSLETTER

    Switch To Full Site